EA200000378A1 - Усеченные по амино-концу мср-2 как антагонисты хемокинов - Google Patents

Усеченные по амино-концу мср-2 как антагонисты хемокинов

Info

Publication number
EA200000378A1
EA200000378A1 EA200000378A EA200000378A EA200000378A1 EA 200000378 A1 EA200000378 A1 EA 200000378A1 EA 200000378 A EA200000378 A EA 200000378A EA 200000378 A EA200000378 A EA 200000378A EA 200000378 A1 EA200000378 A1 EA 200000378A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino
mcp
chemokins
msr
antagonists
Prior art date
Application number
EA200000378A
Other languages
English (en)
Other versions
EA003942B1 (ru
Inventor
Поль Прост
Софи Стрюйф
Йо Ван Дамме
Original Assignee
Апплайд Резеч Системз Арс Холдинг Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200000378(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Апплайд Резеч Системз Арс Холдинг Н.В. filed Critical Апплайд Резеч Системз Арс Холдинг Н.В.
Publication of EA200000378A1 publication Critical patent/EA200000378A1/ru
Publication of EA003942B1 publication Critical patent/EA003942B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Настоящее изобретение относится к усеченным по амино-концу МСР-2, у которых отсутствует NH-концевые аминокислоты, соответствующие аминокислотным остаткам 1, 1-2, 1-3, 1-4 или 1-5 природного МСР-2, и которые обладают антагонистической активностью по отношению к хемокинам, а также к кДНК-последовательностям, кодирующим такие МСР-2; к их применению для лечения и/или диагностики заболеваний, при которых требуется антагонистическая активность против действия хемокинов; и к фармацевтическим композициям, содержащим указанные МСР-2.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000378A 1997-09-29 1998-09-28 Усеченный по амино-концу моноцитарный хемотаксический белок (mcp-2) и способы его использования EA003942B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97116863A EP0906954A1 (en) 1997-09-29 1997-09-29 Amino-terminal truncated c-c chemokines as chemokine antagonist
EP97122471A EP0905240A1 (en) 1997-09-29 1997-12-19 Amino-terminally truncated c-c chemokines as chemokine antagonists
EP98104216A EP0905241A1 (en) 1997-09-29 1998-03-10 Amino-terminally truncated c-c chemokines as chemokine antagonists
PCT/EP1998/006142 WO1999016876A1 (en) 1997-09-29 1998-09-28 Amino-terminally truncated mcp-2 as chemokine antagonists

Publications (2)

Publication Number Publication Date
EA200000378A1 true EA200000378A1 (ru) 2000-10-30
EA003942B1 EA003942B1 (ru) 2003-10-30

Family

ID=8227408

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200000379A EA003940B1 (ru) 1997-09-29 1998-09-28 Усеченный по амино-концу хемокин rantes и способы его использования
EA200000378A EA003942B1 (ru) 1997-09-29 1998-09-28 Усеченный по амино-концу моноцитарный хемотаксический белок (mcp-2) и способы его использования

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200000379A EA003940B1 (ru) 1997-09-29 1998-09-28 Усеченный по амино-концу хемокин rantes и способы его использования

Country Status (29)

Country Link
US (5) US6905676B2 (ru)
EP (6) EP0906954A1 (ru)
JP (2) JP4230659B2 (ru)
KR (2) KR100542934B1 (ru)
CN (3) CN1233415C (ru)
AR (2) AR013529A1 (ru)
AT (3) ATE368742T1 (ru)
AU (2) AU750606B2 (ru)
BG (2) BG64757B1 (ru)
BR (2) BR9812394A (ru)
CA (2) CA2304827A1 (ru)
CY (1) CY1110927T1 (ru)
CZ (2) CZ299479B6 (ru)
DE (3) DE69823218T2 (ru)
DK (3) DK1019507T3 (ru)
EA (2) EA003940B1 (ru)
EE (2) EE200000151A (ru)
ES (3) ES2218860T3 (ru)
HK (3) HK1062637A1 (ru)
HU (2) HU226468B1 (ru)
IL (2) IL135351A (ru)
NO (2) NO20001584D0 (ru)
NZ (3) NZ503235A (ru)
PL (2) PL197569B1 (ru)
PT (3) PT1019507E (ru)
SK (2) SK286495B6 (ru)
UA (2) UA73081C2 (ru)
WO (2) WO1999016877A1 (ru)
ZA (2) ZA988675B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO1999028474A2 (en) * 1997-12-01 1999-06-10 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services Chemokine variants and methods of use
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
EP1167527A1 (en) * 2000-06-22 2002-01-02 Euroscreen S.A. Processed human chemokines PHC-1 and PHC-2
AU1259501A (en) * 1999-10-25 2001-05-08 Euroscreen S.A. Processed human chemokines phc-1 and phc-2
WO2001036459A2 (en) * 1999-11-15 2001-05-25 Forssmann Wolf Georg Novel use of hcc-2
CA2316405A1 (en) * 2000-05-26 2001-11-26 Ian Clark-Lewis Modulation of inflammation by protease products
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB2373785A (en) * 2001-03-28 2002-10-02 Rega Inst For Medical Res Truncating chemokines using dipeptidyl peptidase IV
DE60231057D1 (de) 2001-12-17 2009-03-19 Serono Lab Chemokine mutanten, die als chemokine antagonisten wirken
EP1631680A2 (en) * 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
DE102005049637A1 (de) * 2005-10-14 2007-04-26 Rheinisch-Westfälische Technische Hochschule Aachen Antagonisten gegen die Interaktion von PF4 und RANTES
DK2185719T3 (en) 2007-08-02 2014-02-17 Novimmune Sa ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
WO2011097567A1 (en) * 2010-02-08 2011-08-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Rantes multiplexed assay, rantes variants related to disease, and rantes variants related to enzymatice activity
CN102884194B (zh) 2010-03-11 2015-07-22 健康研究股份有限公司 含增强免疫应答的Fc融合蛋白的方法和组合物
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
CA3101052A1 (en) 2018-05-28 2019-12-05 ORION Biotechnology Switzerland Sarl Methods of inhibiting cerebral inflammation
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01265099A (ja) 1987-10-08 1989-10-23 Stichting Rega Vzw 抗ｈｉｖ活性をもつ３’，−フルオロプリン−２’，３’−ジデオキシリボシド類
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
CZ290850B6 (cs) * 1994-12-08 2002-10-16 Glaxo Group Limited Polypeptid, způsob jeho výroby, kódující DNA nebo RNA, vektor a buňka
AU1532697A (en) * 1996-01-12 1997-08-01 Genetics Institute Inc. Beta-chemokine, h1305 (mcp-2)
EP0889961A2 (en) * 1996-03-27 1999-01-13 Icos Corporation Monocyte chemotactic protein-5 materials and methods
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use

Also Published As

Publication number Publication date
EP1439231B1 (en) 2007-08-01
NO20001609D0 (no) 2000-03-28
CZ299478B6 (cs) 2008-08-06
AU9442098A (en) 1999-04-23
BR9812565A (pt) 2000-08-01
HK1032425A1 (en) 2001-07-20
NZ516027A (en) 2003-05-30
HK1032426A1 (en) 2001-07-20
ATE368742T1 (de) 2007-08-15
NO20001584L (no) 2000-03-27
DE69823218T2 (de) 2004-08-26
EA200000379A1 (ru) 2000-10-30
EE200000151A (et) 2001-02-15
KR100542934B1 (ko) 2006-01-11
JP2001518297A (ja) 2001-10-16
ES2287601T3 (es) 2007-12-16
JP4230659B2 (ja) 2009-02-25
HUP0003563A2 (hu) 2001-02-28
CA2305017A1 (en) 1999-04-08
ATE264390T1 (de) 2004-04-15
EP1439231A2 (en) 2004-07-21
CA2304827A1 (en) 1999-04-08
US6905676B2 (en) 2005-06-14
PL197569B1 (pl) 2008-04-30
ATE263242T1 (de) 2004-04-15
SK286495B6 (sk) 2008-11-06
ZA988676B (en) 1999-12-03
DK1439231T3 (da) 2007-11-05
BR9812394A (pt) 2000-09-12
BG104267A (en) 2000-11-30
CZ299479B6 (cs) 2008-08-06
US20030119148A1 (en) 2003-06-26
CN1271385A (zh) 2000-10-25
EP0906954A1 (en) 1999-04-07
DE69822856T2 (de) 2004-08-19
CN1490049A (zh) 2004-04-21
SK4512000A3 (en) 2000-09-12
JP4233214B2 (ja) 2009-03-04
CY1110927T1 (el) 2015-06-10
NO20001584D0 (no) 2000-03-27
CN1271386A (zh) 2000-10-25
SK286439B6 (sk) 2008-10-07
EA003940B1 (ru) 2003-10-30
AR013528A1 (es) 2000-12-27
PL339545A1 (en) 2000-12-18
NZ503235A (en) 2002-08-28
PL196427B1 (pl) 2008-01-31
IL135351A (en) 2006-08-20
EP0905240A1 (en) 1999-03-31
EP1439231A3 (en) 2004-12-22
WO1999016876A1 (en) 1999-04-08
WO1999016877A1 (en) 1999-04-08
SK4502000A3 (en) 2000-09-12
HUP0003563A3 (en) 2005-11-28
EP1019507A1 (en) 2000-07-19
HUP0003505A3 (en) 2005-11-28
CN1145693C (zh) 2004-04-14
US7326411B2 (en) 2008-02-05
KR100560275B1 (ko) 2006-03-10
PT1019507E (pt) 2004-06-30
NZ503234A (en) 2002-06-28
DE69838188T2 (de) 2007-11-22
UA73081C2 (en) 2005-06-15
HUP0003505A2 (hu) 2001-02-28
AU750341B2 (en) 2002-07-18
PT1439231E (pt) 2007-08-20
US20050201977A1 (en) 2005-09-15
CZ20001146A3 (cs) 2000-09-13
DE69838188D1 (de) 2007-09-13
EE200000152A (et) 2001-02-15
JP2001518296A (ja) 2001-10-16
US20030124677A1 (en) 2003-07-03
HU226468B1 (en) 2008-12-29
ES2218860T3 (es) 2004-11-16
BG104266A (en) 2000-11-30
HK1062637A1 (en) 2004-11-19
EP0905241A1 (en) 1999-03-31
KR20010024213A (ko) 2001-03-26
EA003942B1 (ru) 2003-10-30
PT1021541E (pt) 2004-07-30
UA73080C2 (en) 2005-06-15
HU226414B1 (en) 2008-11-28
IL135352A (en) 2006-08-20
EP1021541A1 (en) 2000-07-26
KR20010024214A (ko) 2001-03-26
ZA988675B (en) 1999-11-24
EP1019507B1 (en) 2004-03-31
CN1233415C (zh) 2005-12-28
CN1148447C (zh) 2004-05-05
US20050220790A1 (en) 2005-10-06
US20050164936A1 (en) 2005-07-28
ES2215324T3 (es) 2004-10-01
NO20001609L (no) 2000-03-28
DE69822856D1 (de) 2004-05-06
US7338653B2 (en) 2008-03-04
DK1021541T3 (da) 2004-08-02
CZ20001147A3 (cs) 2000-09-13
BG64679B1 (bg) 2005-11-30
DK1019507T3 (da) 2004-07-19
AU9747498A (en) 1999-04-23
DE69823218D1 (de) 2004-05-19
PL339559A1 (en) 2000-12-18
AU750606B2 (en) 2002-07-25
BG64757B1 (bg) 2006-02-28
AR013529A1 (es) 2000-12-27
EP1021541B1 (en) 2004-04-14
US6977071B2 (en) 2005-12-20

Similar Documents

Publication Publication Date Title
EA200000378A1 (ru) Усеченные по амино-концу мср-2 как антагонисты хемокинов
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
EA200400149A1 (ru) Бензотиепины, обладающие активностью ингибиторов перемещения желчных кислот в подвздошной кишке и поглощения таурохолата
ATE446313T1 (de) Muteine von tränen-lipocalin
EA200300381A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
ES2031804T3 (es) Derivado del activador de plasminogeno de tipo tisular.
EA199900621A1 (ru) Лечение рассеянного склероза путем приема внутрь или ингаляции сополимера-1
ITPD920071A1 (it) Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo
ES2113957T3 (es) Preparacion farmaceutica conteniendo un agente uricosurico y un antagonista de aminoacidos excitadores.
DE69033521D1 (de) Verwendung von arginin als immunstimulator
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
ATE395602T1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
EA199900755A1 (ru) Производное хинолин-2-карбоновой кислоты и его применение в качестве антагониста возбуждающих аминокислот
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
EA199901001A1 (ru) Бетаины, используемые в качестве адъювантов для проверки чувствительности и антимикробной терапии
EA199700451A1 (ru) Мономерные 4,4-(дизамещенные) циклогексан-1-олы и родственные соединения
DK0811068T3 (da) Humane DNase I varianter
IL175019A0 (en) Cxcl8 antagonists, their preparation and use

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU